BMO upgrades Sarepta on Elevidys uptake, pipeline prospects
PositiveFinancial Markets

BMO has upgraded its outlook on Sarepta Therapeutics, citing strong uptake of its gene therapy product Elevidys and promising prospects for its pipeline. This upgrade is significant as it reflects growing confidence in Sarepta's ability to deliver innovative treatments for rare diseases, potentially leading to improved patient outcomes and increased investor interest.
— Curated by the World Pulse Now AI Editorial System